Blab Business
Hims & Hers Shares Slip After Q2 Loss, Regulatory Scrutiny Persists
Shares of Hims & Hers Health (NYSE: HIMS) slipped roughly 3% on Tuesday, a sharp after‑hours decline that followed a 7% opening drop after the company’s earnings announcement. The move came as the company reported a second‑quarter loss of $0.37 per share— a reversal of the $0.17 profit it posted a year earlier.
Revenue for the quarter rose 38% to $753.2 million, beating analyst expectations. Yet the company booked a net loss of $86.3 million, a swing from a $42.5 million profit in the same period last year. Gross margin contracted to 64% from 76% year‑over‑year, a change largely driven by a one‑time $81 million expense. That outlay covered the purchase of Australian digital‑health firm Eucalyptus, restructuring costs tied to a shift in the weight‑loss strategy, and legal reserves related to an ongoing Federal Trade Commission (FTC) lawsuit.
Hims & Hers has been moving away from its original model of selling copycat GLP‑1 weight‑loss medications. In March, the company announced a partnership with Novo Nordisk to distribute a broader array of FDA‑approved GLP‑1 treatments. The transition is intended to align the U.S. portfolio with the firm’s global strategy and to phase out compounded drugs that have attracted regulatory attention.
The FTC lawsuit, filed July 29, accuses Hims & Hers of sharing private health data with advertising platforms Meta and Snap and of making subscription cancellations difficult. The company has denied the allegations and said it will defend itself. CFO Yemi Okupe told the earnings‑call audience on Monday, “We are confident in our position and intend to defend it vigorously.”
Despite the quarterly loss, Hims & Hers added 300,000 net new subscribers and finished the period with nearly 3 million subscribers worldwide. The firm lifted its fiscal‑2026 revenue outlook to between $3.1 billion and $3.3 billion, topping the $2.93 billion consensus estimate.
The stock’s performance has been weighed by the regulatory climate surrounding GLP‑1 drugs and data‑privacy concerns. Earlier this year, the company saw a drawdown as investors assessed the legal risks. Year‑to‑date, the share price has fallen more than 4%.
Analysts point to the one‑time costs and restructuring expenses as key drivers of the margin compression seen in the quarter. The net loss per share of $0.37 missed the consensus estimate of $0.05, and the market reacted swiftly, with shares falling 6% in extended trading.
Looking ahead, Hims & Hers is concentrating on its AI‑powered consumer health platform, highlighted in investor slides released August 10. The company’s strategy is to broaden its product portfolio through partnerships with pharmaceutical manufacturers while addressing the regulatory challenges that have emerged.
The next earnings call will offer further insight into how the shift to branded weight‑loss drugs and the FTC lawsuit will affect financial performance. Investors will also monitor subscriber growth, margin recovery, and any additional regulatory developments.
In short, Hims & Hers’ shares fell after a quarterly loss and margin decline, but the company’s pivot to branded GLP‑1 treatments and its AI platform may set the stage for future growth. The ongoing FTC lawsuit and restructuring costs remain key risks that could shape investor sentiment in the months ahead.
Revenue for the quarter rose 38% to $753.2 million, beating analyst expectations. Yet the company booked a net loss of $86.3 million, a swing from a $42.5 million profit in the same period last year. Gross margin contracted to 64% from 76% year‑over‑year, a change largely driven by a one‑time $81 million expense. That outlay covered the purchase of Australian digital‑health firm Eucalyptus, restructuring costs tied to a shift in the weight‑loss strategy, and legal reserves related to an ongoing Federal Trade Commission (FTC) lawsuit.
Hims & Hers has been moving away from its original model of selling copycat GLP‑1 weight‑loss medications. In March, the company announced a partnership with Novo Nordisk to distribute a broader array of FDA‑approved GLP‑1 treatments. The transition is intended to align the U.S. portfolio with the firm’s global strategy and to phase out compounded drugs that have attracted regulatory attention.
The FTC lawsuit, filed July 29, accuses Hims & Hers of sharing private health data with advertising platforms Meta and Snap and of making subscription cancellations difficult. The company has denied the allegations and said it will defend itself. CFO Yemi Okupe told the earnings‑call audience on Monday, “We are confident in our position and intend to defend it vigorously.”
Despite the quarterly loss, Hims & Hers added 300,000 net new subscribers and finished the period with nearly 3 million subscribers worldwide. The firm lifted its fiscal‑2026 revenue outlook to between $3.1 billion and $3.3 billion, topping the $2.93 billion consensus estimate.
The stock’s performance has been weighed by the regulatory climate surrounding GLP‑1 drugs and data‑privacy concerns. Earlier this year, the company saw a drawdown as investors assessed the legal risks. Year‑to‑date, the share price has fallen more than 4%.
Analysts point to the one‑time costs and restructuring expenses as key drivers of the margin compression seen in the quarter. The net loss per share of $0.37 missed the consensus estimate of $0.05, and the market reacted swiftly, with shares falling 6% in extended trading.
Looking ahead, Hims & Hers is concentrating on its AI‑powered consumer health platform, highlighted in investor slides released August 10. The company’s strategy is to broaden its product portfolio through partnerships with pharmaceutical manufacturers while addressing the regulatory challenges that have emerged.
The next earnings call will offer further insight into how the shift to branded weight‑loss drugs and the FTC lawsuit will affect financial performance. Investors will also monitor subscriber growth, margin recovery, and any additional regulatory developments.
In short, Hims & Hers’ shares fell after a quarterly loss and margin decline, but the company’s pivot to branded GLP‑1 treatments and its AI platform may set the stage for future growth. The ongoing FTC lawsuit and restructuring costs remain key risks that could shape investor sentiment in the months ahead.
